Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:38:24 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Q:ALNY - ALNYLAM PHARMACEUTICALS INC - https://www.alnylam.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ALNY - Q1.5320.00·326.000.1328.16-3.08-0.91,476.9485,82029,291331.61  340.07  326.51495.55  205.8719:08:43Jan 2915 min RT 2¢

Recent Trades - Last 10 of 29291
Time ETExPriceChangeVolume
19:08:43Q324.66-6.581
19:08:22Q325.92-5.3210
19:08:22Q324.80-6.4410
19:08:22Q324.00-7.241
18:50:56Q320.00-11.242
18:02:59Q326.97-4.271
18:01:03Q325.92-5.321
18:00:52Q327.06-4.186
17:52:55Q326.10-5.141
17:19:49Q328.15-3.092

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-29 08:00U:ALNYNews ReleaseAlnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results
2026-01-11 17:00U:ALNYNews ReleaseAlnylam Launches "Alnylam 2030" Strategy to Drive Next Era of Growth and Patient Impact
2026-01-05 09:15U:ALNYNews ReleaseAlnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference
2025-12-17 08:00U:ALNYNews ReleaseAlnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics
2025-12-11 07:00U:ALNYNews ReleaseAlnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027
2025-12-03 08:00U:ALNYNews ReleaseAlnylam Pharmaceuticals Announces Changes to Board of Directors
2025-11-08 16:57U:ALNYNews ReleaseNew Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
2025-11-04 08:00U:ALNYNews ReleaseAlnylam to Webcast Presentations at Upcoming November Investor Conferences
2025-10-30 08:00U:ALNYNews ReleaseAlnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress
2025-10-16 08:00U:ALNYNews ReleaseAlnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results
2025-10-01 07:30U:ALNYNews ReleaseAlnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran
2025-09-28 11:13U:ALNYNews ReleaseNew Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
2025-09-18 09:15U:ALNYNews ReleaseAlnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine
2025-09-09 23:16U:ALNYNews ReleaseAlnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes
2025-09-08 16:15U:ALNYNews ReleaseAlnylam Announces Proposed Offering of $500 Million Convertible Senior Notes
2025-08-31 05:15U:ALNYNews ReleaseNew Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran's Long-Term Cardiovascular Benefit in ATTR-CM
2025-08-30 10:30U:ALNYNews ReleaseAlnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
2025-08-11 08:00U:ALNYNews ReleaseAlnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025
2025-08-05 08:00U:ALNYNews ReleaseAlnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference
2025-07-31 08:00U:ALNYNews ReleaseAlnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress